Search

Displaying results 1621 - 1630 of 8468 in total
  1. Drug

    Luspatercept

    go.drugbank.com/drugs/DB12281
    ApprovedInvestigational

    [A187829,L42455] It was first approved for use in the United States in November 2019 under the brand name Reblozyl® for the treatment of anemia in patients with beta thalassemia who require regular blood … [L42455] Luspatercept is novel in that it ameliorates anemia via action on late-stage erythropoiesis, in contrast to typical erythropoiesis-stimulating agents (ESAs), such as [darbepoetin alfa] and [epoetin

  2. Drug

    Betrixaban

    go.drugbank.com/drugs/DB12364
    Approved

    It was selected among all lead compounds due to its low hERG channel affinity while sustaining its factor Xa inhibition capacity [A27286]. … VTE can be manifested as deep vein thrombosis or pulmonary embolism and it is a leading cause of preventable death in hospitalized patients [A27287].

  3. Drug

    Palovarotene

    go.drugbank.com/drugs/DB05467
    Approved

    It first garnered interest as a potential treatment for emphysema but was eventually recognized as a potential novel therapy for patients with FOP. … [L39990,L40020] It has been granted rare pediatric disease and breakthrough therapy designations from the US FDA, although a previously submitted NDA was withdrawn in August 2021 pending the resubmission

  4. Drug

    Avobenzone

    go.drugbank.com/drugs/DB09495
    ApprovedInvestigational

    Avobenzone has the ability to absorb ultraviolet light over wider range of wavelengths. It is included in many commercially available sunscreens which are used as wide spectrum sunscreens. … Avobenzone has an absorption maximum of 357 nm. Sunscreens containing avobenzone is indicated for providing protection from the sun.

    Mixtures: CARROT SUN SPF30 PA Plus Plus, Lovely Me:ex Bb Cream SPF 20/pa++
  5. Drug

    Mavacamten

    go.drugbank.com/drugs/DB14921
    ApprovedInvestigational

    [A248440] Mavacamten was also approved by Health Canada in October 2022 and by EMA in July 2023 for the same indication.[L44106,L47471]

  6. Drug

    Exenatide

    go.drugbank.com/drugs/DB01276
    ApprovedInvestigational

    Exenatide was given FDA approval on April 28, 2005[L6106]. It is available as immediate- and extended-release formulations. … [L42685,L42690] Bydureon, the brand name product of extended-release exenatide in an injectable suspension, was discontinued in 2021.

  7. Drug

    Lactitol

    go.drugbank.com/drugs/DB12942
    Approved

    [A190918] It is used in food manufacturing as a nutritive sweetener and is approximately 35% as sweet as table sugar (i.e. [sucrose]). … [A190912] Clinically, lactitol has been investigated for use as an osmotic laxative and, along with other non-absorbable disaccharides such as [lactulose], in the treatment of hepatic encephalopathy in

  8. Drug

    Camazepam

    go.drugbank.com/drugs/DB01489
    ExperimentalIllicit

    Camazepam also has less side effects, such as impaired cognition and reaction times, compared to other benzodiazepines. … In the United States camazepam is regulated as a Schedule IV controlled substance.

  9. Drug

    Protamine sulfate

    go.drugbank.com/drugs/DB09141
    ApprovedInvestigational

    Since it's earliest discovery in salmon rine sperm heads in the late 1800's to its formal introduction via US FDA approval in 1939, protamine sulfate has occupied an important therapeutic niche as perhaps … As a consequence, whenever protamine sulfate use is clinically considered, careful consideration must be given as to whether the use of the agent could decrease the safety of the procedure or worsen the

  10. Drug

    Niclosamide

    go.drugbank.com/drugs/DB06803
    ApprovedInvestigationalVet approved

    Niclosamide, once marketed in the US under the brand name Niclocide, was voluntarily withdrawn from market by Bayer in 1996.[L11860]